Bio Assays - Commentary – First Supplement to USP 35-NF 30
Amongst others, the USP published the received comments and responses to General Chapter/Section: <1032> Design and Development of Biological Assays in the Commentary – First Supplement to USP 35-NF 30.
The USP received 13 comments to different parts of this chapter. Comments to the following topics are included:
- Necessary Harmonization with compendial references e.g. European Pharmacopoiea
- Helpful case study examples that illustrate the application
- The need that the assay acheive a specific observable response
- Assessment of similarity using the entire concentration-response curve, including the asymptotes.
- Potency assay for assessment of stability
- Need of documenting the source of assay's cell line
The complete comments can be found at Commentary – First Supplement to USP 35-NF 30.
In this respect you may also want to pay attention to ECA's New Education Course on "Bioassays, and Bioanalytics" from 27-28 March 2012 in Copenhagen, Denmark.
Author:
Axel H. Schroeder
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
27.08.2025FDA Warning Letter: Missing Identity Tests, Unverified CoAs, and Inadequate DEG/EG Controls
20.08.2025USP Responds to Comments on Chapter <202> HPTLC Identification of Fixed Oils
13.08.2025USP publishes Comments rereived on Chapter <317>
13.08.2025FDA Issues Warning Letter to Contract Testing Laboratory for Inadequate OOS Investigations
06.08.2025EMA publishes Overview of Comments received on ICH M13B Guideline on Bioequivalence
06.08.2025FDA Warning Letter: Company Voluntarily Ceases Drug Production